4Tissue secures €1.5M funding and appoints new board chair

4Tissue, a biotechnology pioneer based in Ghent, Belgium, has announced an additional €1.5 million funding round to advance its bioresorbable hydrogel technology, critical for breast reconstruction and tissue regeneration, with a specific focus on women's health. The funding comprises €1 million in equity investments and grants from strategic investors, intending to support upcoming clinical studies and enhance regulatory and quality control expertise. Alongside this financial milestone, 4Tissue has appointed Dr. Katleen Verleysen as the independent chair of the board. Dr. Verleysen, with over 20 years of life sciences experience and notable achievements in clinical and market success, is expected to guide the company through further funding rounds and strategic progression. The hydrogel technology developed by 4Tissue offers a less invasive and more efficient alternative to traditional methods, aligning with the company’s mission to innovate regenerative medicine. Dr. Verleysen's appointment marks a significant step as 4Tissue drives towards a revolutionary impact in the sector, aiming to enhance the lives of women globally through advanced breast reconstruction solutions.